BOT - Post Approval Takeover Predictions

Vince Takeover Track record :

Medicis,
2010 / 2011 revenues of around 700 million, giving a net profit of approximately 123.3 million. Several successful products generating revenue. Not much growth between 2010 and 2011. ( EPS almost identical ). Market value 1.89 Billion USD, was purchased for 2.4 Billion USD.

Anacor,
Purchased May 16 for 5.2 Billion ( Note that Anacor had been previously up to around 6 billion in stock price prior to the takeover.) . Pfizer thought there was potential for 2 billion in yearly sales from crisaborole once FDA approved. At that time, Anacor had made a recent 2015 net loss of 61 million, with a total of 69.7 million in revenue from their only other existing drug Kerydin. Crisaborole was approved later in Dec 2016. It then went on to do US$147 million in sales in 2018, and US$138 million in sales in 2019. Crisaborole, has been rapidly withdrawn from the European market (March 2020 - February 2022). So was anacor Overhyped and overpriced..... looks like it turned out that way, it was overpriced even before the takeover deal by the stock market.

Botanix
Priced currently around 300 Million USD
New chemical entity, high area of need, patent protected, innovative platform......?????????
9 figure profits expected on matching Kakens' Japanese sales curve.
Underpriced and undervalued.... I think so.